Brief: Nervgen Announces First Participant Dosed In Restore, A Phase 3 Registrational Study Evaluating NVG-291 In Chronic Spinal Cord Injury
12/10/2026 12:19
BRIEF-Nervgen Announces First Participant Dosed In Restore, A Phase 3 Registrational Study Evaluating NVG-291 In Chronic Spinal Cord Injury Oct 12 (Reuters) - NervGen Pharma Corp NGEN.O:
NERVGEN ANNOUNCES FIRST PARTICIPANT DOSED IN RESTORE, A PHASE 3 REGISTRATIONAL STUDY EVALUATING NVG-291 IN CHRONIC SPINAL CORD INJURY
NERVGEN PHARMA CORP - ENROLLMENT COMPLETION FOR RESTORE EXPECTED H2 2027; TOPLINE DATA IN H1 2028
Source text: ID:nGNX68H7fw
Further company coverage: NGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nervgen Pharma
See all newsBrief: Nervgen Announces First Participant Dosed In Restore, A Phase 3 Registrational Study Evaluating NVG-291 In Chronic Spinal Cord Injury
Brief: NervGen To Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
Brief: Nervgen Reports Second Quarter 2026 Financial Results And Provides Business Updates
Brief: Nervgen Pharma Corp - Nvg-291 Shows Statistically Significant Gait Quality Improvement In Phase 1B/2A Connect Sci Study
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive